Evidenzbasierte und stadienadaptierte Therapie chronisch-entzündlicher Darmerkrankungen: Pro Top-down

Schlüsselwörter

Morbus Crohn - Colitis ulcerosa - Biologika

Keywords

Crohn’s disease - ulcerative colitis - biologicals

• Literatur

• 1 Baert F et al. Mucosal healing predicts sustained clinical remission in patients with early-stage. Gastroenterology 2010; 138: 463-468
• 2 Colombel JF et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
• 3 D'Haens G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease. Lancet 2008; 371: 660-667
• 4 Louis E et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy afterinfliximab therapy is stopped. Gastroenterology 2012; 142: 63-70
• 5 Panaccione R et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. Gastroenterology 2011; 140 (Suppl. 01) S134
• 6 Schreiber S et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis 2013; 7: 213-221